IPTG

Wuhan BJM Pharm Inc, established in May 2013 and headquartered in Wuhan's Optics Valley district, is an integrated manufacturer, exporter, and trading company producing pharmaceutical intermediates and active ingredients alongside amino acids and UV absorbers. Its intermediate portfolio includes Erdosteine, Pirfenidone, Letrozole, Oxybutynin, and Dapagliflozin precursors, while its UV-absorber line covers Octocrylene, Ethylhexyl Triazone (UVT-150), TINSORB S/BEMT, DHHB, and Polysilicone-15. The company operates two production bases in Jingmen and Jingzhou plus a dedicated R&D center in Donghu Hi-Tech Zone opened in 2022, supported by more than 90% university-educated staff and eight invention patents. With annual sales of roughly 180 million yuan and about 15 million US dollars in export revenue, Wuhan BJM ships to customers across Europe, the Americas, Japan, South Korea, and India, offering CRO contract research services, OEM production, and the flexibility to accept custom specifications and small orders.